Core Insights - Cognizant reported revenue of $5.25 billion for the quarter ended June 2025, reflecting an 8.1% increase year-over-year and surpassing the Zacks Consensus Estimate of $5.19 billion by 1.01% [1] - Earnings per share (EPS) for the quarter was $1.31, up from $1.17 in the same quarter last year, exceeding the consensus EPS estimate of $1.26 by 3.97% [1] Revenue Performance by Segment - Health Sciences revenue was $1.55 billion, slightly below the average estimate of $1.61 billion, representing a year-over-year increase of 6.2% [4] - Communications, Media and Technology revenue reached $841 million, exceeding the average estimate of $826.36 million, with a year-over-year growth of 3.1% [4] - Products and Resources generated $1.31 billion, surpassing the estimated $1.25 billion, marking a significant year-over-year increase of 16% [4] - Financial Services revenue was $1.55 billion, slightly above the average estimate of $1.52 billion, reflecting a year-over-year growth of 6.9% [4] Stock Performance - Cognizant's shares have declined by 6.9% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Cognizant (CTSH) is expected to report quarterly earnings of $1.26 per share, a 7.7% increase year-over-year, with revenues projected at $5.19 billion, reflecting a 7.1% year-over-year growth [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 0.1%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Products and Resources' at $1.25 billion, representing an 11% increase from the previous year [5]. - 'Revenue- Health Sciences' is projected to be $1.61 billion, indicating a 10.1% year-over-year change [5]. - 'Revenue- Financial Services' is expected to reach $1.52 billion, reflecting a 5.3% increase year-over-year [5]. - 'Revenue- Communications, Media and Technology' is forecasted at $826.36 million, showing a 1.3% year-over-year change [6]. Market Performance - Cognizant shares have returned -1.1% over the past month, contrasting with the Zacks S&P 500 composite's +4.6% change [6]. - With a Zacks Rank 2 (Buy), Cognizant is anticipated to outperform the overall market in the near future [6].

Group 1 - The upcoming report from Cognizant (CTSH) is expected to reveal quarterly earnings of $1.19 per share, indicating an increase of 6.3% compared to the year-ago period [1] - Analysts forecast revenues of $5.07 billion, representing an increase of 6.5% year over year [1] - The consensus EPS estimate for the quarter has been revised 0.5% lower over the last 30 days, reflecting a reevaluation of initial estimates by analysts [1] Group 2 - The consensus estimate for 'Revenue- Products and Resources' stands at $1.27 billion, suggesting a change of +12.2% year over year [4] - The average prediction for 'Revenue- Health Sciences' is $1.55 billion, indicating a change of +9.7% from the year-ago quarter [4] - Analysts suggest that 'Revenue- Financial services' will likely reach $1.43 billion, with a change of +3.2% from the year-ago quarter [4] Group 3 - The consensus among analysts for 'Revenue- Communications, Media and Technology' is expected to reach $835.39 million, indicating a year-over-year change of +1.1% [5] - Shares of Cognizant have demonstrated returns of -5.1% over the past month compared to the Zacks S&P 500 composite's -0.8% change [5] - Cognizant holds a Zacks Rank 3 (Hold), indicating expectations to mirror overall market performance in the near future [5]